#United States #financial results #Milford #Waters Corporation #Q2 2026

Waters Corporation Reports Second Quarter 2026 Financial Results

Waters Corporation (NYSE: WAT) recently unveiled its financial performance for the second quarter of 2026, showcasing a remarkable total revenue of $1.645 billion. This performance not only surpassed the upper limit of the company’s guidance but was also a testament to strong market demand and successful execution of its growth strategy.

Key Highlights

The revenue breakdown reflects both organic growth and contributions from recently acquired businesses, specifically the Biosciences and Diagnostic Solutions (BDS) segments.

• - Organic Revenue: Totaling $828 million, which represents a 7% increase compared to the same period in 2025, with a notable 9% growth in constant currency.
• - Biosciences and Diagnostics: Generated $817 million, which exceeded projections by $15 million and marked a 4% growth on a year-over-year basis. This segment experienced a resurgence as operational improvements began to pay dividends.
• - The Analytical Sciences Division (ASD) saw instrument sales grow by 8% with consumables experiencing a double-digit rise, driven by increasing demands from pharmaceutical and agriculture markets.

Despite reporting a GAAP EPS loss of $1.39, Waters Corporation's adjusted EPS reached $3.05, aligning tightly with their guidance and reflecting early cost-reduction initiatives that mitigated the impact of unfavorable currency fluctuations.

Strategic Moves and Future Guidance

CEO Udit Batra highlighted the exceptional performance across all divisions, stating, “Our organic revenue grew 9% in constant currency, which underscores our strategic focus on innovation and market expansion.” The company has altered its full-year guidance based on the strong results and market conditions, projecting organic revenue growth of 7% to 9% for 2026. Furthermore, Waters expects full-year revenue from acquired businesses to settle around $3.045 billion, culminating in total reported revenue predictions of $6.415 to $6.476 billion for the year.

Segment Performance

1. Analytical Sciences Division: Reports revenue of $669 million, up from $627 million in the previous year. This reflects the division's robust demand particularly for lab instruments.
2. Biosciences Division: Posts $368 million, slightly higher than the previous year's revenue of $358 million.
3. Advanced Diagnostics Unit: Recorded revenue of $521 million, showcasing extraordinary growth from $62 million in the prior year as it significantly ramped up its operations.
4. Materials Sciences Division: Improved figures, with reported revenue of $87 million versus $82 million, indicating steady growth across its markets.

Outlook for the Third Quarter

Looking ahead, Waters Corporation anticipates organic constant currency revenue growth in the range of 8% to 10% for Q3 2026, with total quarter revenue expected between $1.745 billion and $1.762 billion. Furthermore, the third quarter adjusted EPS estimates anticipate a growth range of 16% to 19% year-over-year, reinforcing the company’s optimistic outlook as they continue to navigate through diverse market conditions.

Overall, Waters Corporation is positioned for a year of significant growth and innovation, bolstered by strategic acquisitions and a deep commitment to operational excellence across its divisions. With a forecasted adjusted EPS growth of 10% to 12%, stakeholders can expect continuing advancements as the company aims for an even stronger market presence.